Main Menu

Incubator's latest tenant

Firm developing diagnosis device opts for BioCity

Diane Harbison BioCityA company developing a device to help in the diagnosis of diseases is the latest tenant at the BioCity Scotland incubator on eastern edge of Glasgow.

The move comes after Relitect secured £750,000 from IP Group, with co-investment from IP Venture Fund II and Scottish Enterprise’s investment arm, Scottish Investment Bank, via the Scottish co-investment Fund.

The investment will help the company build its internal research and development capability, as well as manufacture and test prototype devices.

Relitect is developing a new electronic device to be used across the clinical diagnostics and life sciences industries to support drug development and provide improved disease diagnosis.

The team based at BioCity Scotland will lead the research and development required to fully commercialise the technology.

Alan Thomson, technical director at Relitect said: “Choosing the right premises was important for the company to ensure that we have the right infrastructure to achieve our short term objectives, as well as our goals for long term growth.

“We chose BioCity Scotland because of the quality of laboratory space and the minimal work needed to get our laboratory up and running, as well as the comprehensive support available from the Biocity team.”

Dr Diane Harbison, managing director of BioCity Scotland said: “We are delighted that Relitect has chosen BioCity Scotland as the place where it will develop its exciting new technology, and we are really looking forward to supporting the ongoing development of the company.”

“As well as providing high spec laboratories and office space, BioCity Scotland also offers access to expertise, finance and a community of like-minded people, and it’s that additional support that really helps our tenant companies to achieve such a high success rate.”

Photo: Diane Harbison of BioCity Scotland 

 

Share The News Tweet about this on TwitterShare on FacebookShare on Google+Email this to someoneShare on LinkedIn





Leave a Reply

Your email address will not be published. Required fields are marked as *

*